MX2016011580A - Dominios de fibronectina tipo iii que se unen a albumina de suero. - Google Patents
Dominios de fibronectina tipo iii que se unen a albumina de suero.Info
- Publication number
- MX2016011580A MX2016011580A MX2016011580A MX2016011580A MX2016011580A MX 2016011580 A MX2016011580 A MX 2016011580A MX 2016011580 A MX2016011580 A MX 2016011580A MX 2016011580 A MX2016011580 A MX 2016011580A MX 2016011580 A MX2016011580 A MX 2016011580A
- Authority
- MX
- Mexico
- Prior art keywords
- serum albumin
- type iii
- fibronectin type
- iii domains
- binding fibronectin
- Prior art date
Links
- 102000007562 Serum Albumin Human genes 0.000 title abstract 3
- 108010071390 Serum Albumin Proteins 0.000 title abstract 3
- 102000002090 Fibronectin type III Human genes 0.000 title abstract 2
- 108050009401 Fibronectin type III Proteins 0.000 title abstract 2
- 230000004927 fusion Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a polipéptidos los cuales incluyen el décimo dominio de fibronectina tipo III (10Fn3) que se une a albúmina de suero, con sustituciones del bucle del polo sur. La invención, además, se refiere a moléculas de fusión que comprenden un 10Fn3 de unión a albúmina de suero unido a una proteína heteróloga para uso en aplicaciones de diagnóstico y terapéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461968181P | 2014-03-20 | 2014-03-20 | |
PCT/US2015/021535 WO2015143199A1 (en) | 2014-03-20 | 2015-03-19 | Serum albumin-binding fibronectin type iii domains |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016011580A true MX2016011580A (es) | 2016-11-29 |
Family
ID=52808189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016011580A MX2016011580A (es) | 2014-03-20 | 2015-03-19 | Dominios de fibronectina tipo iii que se unen a albumina de suero. |
Country Status (13)
Country | Link |
---|---|
US (3) | US10442851B2 (es) |
EP (2) | EP3572424B1 (es) |
JP (2) | JP6591437B2 (es) |
KR (2) | KR20220162886A (es) |
CN (2) | CN106170494B (es) |
AU (1) | AU2015231170B2 (es) |
CA (1) | CA2943241C (es) |
EA (2) | EA034886B1 (es) |
ES (2) | ES2736127T3 (es) |
IL (2) | IL275497B (es) |
MX (1) | MX2016011580A (es) |
SG (1) | SG11201607820QA (es) |
WO (1) | WO2015143199A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
EA034886B1 (ru) | 2014-03-20 | 2020-04-02 | Бристол-Майерс Сквибб Компани | Связывающие сывороточный альбумин домены фибронектина iii типа |
EP4218832A3 (en) | 2014-11-25 | 2023-08-23 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain |
EP3702367B1 (en) | 2014-11-25 | 2024-05-15 | Bristol-Myers Squibb Company | Novel pd-l1 binding polypeptides for imaging |
ES2967078T3 (es) | 2015-09-23 | 2024-04-25 | Bristol Myers Squibb Co | Dominios de fibronectina de tipo III de unión a seroalbúmina con velocidad de disociación rápida |
CN108463243B (zh) * | 2015-11-19 | 2022-06-14 | 夏尔人类遗传性治疗公司 | 重组人c1酯酶抑制剂及其用途 |
US11339225B2 (en) | 2016-05-12 | 2022-05-24 | Asclepius (Suzhou) Technology Company Group, Co., Ltd. | Bispecific antigen-binding construct and preparation method and use thereof |
CN107365387B (zh) * | 2016-05-12 | 2022-03-15 | 阿思科力(苏州)生物科技有限公司 | 一种双特异性抗原结合构建体及其制备方法和应用 |
US11344639B2 (en) | 2016-06-01 | 2022-05-31 | Bristol-Myers Squibb Company | PET imaging with PD-L1 binding polypeptides |
WO2017210335A1 (en) | 2016-06-01 | 2017-12-07 | Bristol-Myers Squibb Company | Imaging methods using 18f-radiolabeled biologics |
EP3463430A4 (en) | 2016-06-03 | 2020-02-12 | Janssen Biotech, Inc. | SERUM ALBUMIN BINDING FIBRONECTIN TYPE III DOMAINS |
CA3043179A1 (en) * | 2016-11-10 | 2018-05-17 | Keros Therapeutics, Inc. | Gdnf fusion polypeptides and methods of use thereof |
US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
US10611823B2 (en) | 2016-12-14 | 2020-04-07 | Hanssen Biotech, Inc | CD137 binding fibronectin type III domains |
US10626165B2 (en) | 2016-12-14 | 2020-04-21 | Janssen Biotech, Inc. | CD8a-binding fibronectin type III domains |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
MX2020012252A (es) * | 2018-05-14 | 2021-04-28 | Werewolf Therapeutics Inc | Polipeptidos de interleucina 12 activables y metodos de uso de los mismos. |
WO2019222529A1 (en) | 2018-05-16 | 2019-11-21 | Lib Therapeutics, Llc | Compositions comprising pcsk9-binding molecules and methods of use |
WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
WO2021076546A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Cd71 binding fibronectin type iii domains |
WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
AU2020405107A1 (en) * | 2019-12-18 | 2022-07-14 | Aro Biotherapeutics Company | Serum albumin-binding fibronectin type III domains and uses thereof |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
CN112067806A (zh) * | 2020-09-25 | 2020-12-11 | 徐州医科大学 | Caspase-1在制备提高CAR-T治疗效果的药物中的应用 |
KR102284800B1 (ko) * | 2020-12-30 | 2021-08-03 | 주식회사 하플사이언스 | 재조합 세포외 기질 단백질의 생산을 위한 동물세포 배양용 배지 조성물 및 이를 이용한 방법 |
CN113307857B (zh) * | 2021-01-14 | 2022-11-01 | 艾时斌 | 从表皮生长因子、凝集素和Tat蛋白衍生的支架蛋白 |
IL307582A (en) | 2021-04-14 | 2023-12-01 | Aro Biotherapeutics Company | CD71-binding domains of the fibronectin type |
WO2022229854A1 (en) * | 2021-04-29 | 2022-11-03 | Novartis Ag | Hypersialylating cells |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
TW202332694A (zh) | 2021-10-07 | 2023-08-16 | 英商阿凡克塔生命科學公司 | 血清半衰期延長之pd-l1結合多肽 |
WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
CN115386009B (zh) * | 2022-04-26 | 2023-12-01 | 江苏靶标生物医药研究所有限公司 | 一种膜联蛋白v与血管生成抑制剂融合蛋白的构建方法和应用 |
WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
CN115724951B (zh) * | 2022-11-15 | 2023-10-03 | 怡道生物科技(苏州)有限公司 | 与11型hpv结合的抗体或其抗原结合片段及其应用 |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6361943B1 (en) | 1996-10-17 | 2002-03-26 | Mitsubishi Chemical Corporation | Molecule that homologizes genotype and phenotype and utilization thereof |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US5641648A (en) | 1986-11-04 | 1997-06-24 | Protein Polymer Technologies, Inc. | Methods for preparing synthetic repetitive DNA |
US5770697A (en) | 1986-11-04 | 1998-06-23 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US6018030A (en) | 1986-11-04 | 2000-01-25 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US5514581A (en) | 1986-11-04 | 1996-05-07 | Protein Polymer Technologies, Inc. | Functional recombinantly prepared synthetic protein polymer |
DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
WO1992002536A1 (en) | 1990-08-02 | 1992-02-20 | The Regents Of The University Of Colorado | Systematic polypeptide evolution by reverse translation |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5773574A (en) | 1990-12-03 | 1998-06-30 | The Scripps Research Institute | Polypeptides for promoting cell attachment |
US5235041A (en) | 1990-12-28 | 1993-08-10 | Protein Polymer Technologies, Inc. | Purification of structurally ordered recombinant protein polymers |
US5792742A (en) | 1991-06-14 | 1998-08-11 | New York University | Fibrin-binding peptide fragments of fibronectin |
WO1993003172A1 (en) | 1991-08-01 | 1993-02-18 | University Research Corporation | Systematic polypeptide evolution by reverse translation |
DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
WO1994017097A1 (en) | 1993-01-19 | 1994-08-04 | Regents Of The University Of Minnesota | Synthetic fibronectin fragments as inhibitors of retroviral infections |
AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US5559000A (en) | 1995-01-18 | 1996-09-24 | The Scripps Research Institute | Encoded reaction cassette |
DE19646372C1 (de) | 1995-11-11 | 1997-06-19 | Evotec Biosystems Gmbh | Genotyp und Phänotyp koppelnde Verbindung |
GB9618960D0 (en) | 1996-09-11 | 1996-10-23 | Medical Science Sys Inc | Proteases |
US5922676A (en) | 1996-09-20 | 1999-07-13 | The Burnham Institute | Methods of inhibiting cancer by using superfibronectin |
RU2233878C2 (ru) | 1997-01-21 | 2004-08-10 | Дзе Дженерал Хоспитал Корпорейшн | Способ отбора желательного белка и нуклеиновой кислоты, средства для его осуществления |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
JP4187277B2 (ja) | 1997-04-30 | 2008-11-26 | エンゾン ファーマシューティカルズ, インコーポレイテッド | グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用 |
WO1998056915A2 (en) | 1997-06-12 | 1998-12-17 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
US6159722A (en) | 1997-12-03 | 2000-12-12 | Boehringer Mannheim Gmbh | Chimeric serine proteases |
IL138668A0 (en) | 1998-04-03 | 2001-10-31 | Phylos Inc | Addressable protein arrays |
WO2000034784A1 (en) | 1998-12-10 | 2000-06-15 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
GB9827228D0 (en) | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
ATE269357T1 (de) | 1999-04-28 | 2004-07-15 | Univ Texas | Zusammensetzungen und verfahren zur krebsbehandlung durch die selektive hemmung von vegf |
IL147037A0 (en) | 1999-07-27 | 2002-08-14 | Phylos Inc | Peptide acceptor ligation methods |
WO2001072829A2 (en) | 2000-03-31 | 2001-10-04 | Institut Pasteur | Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
EP1364009A2 (en) | 2000-06-15 | 2003-11-26 | Board of Regents, The University of Texas System | Regulatable, catalytically active nucleic acids |
EP1301538B1 (en) | 2000-07-11 | 2015-12-09 | Research Corporation Technologies, Inc | Artificial antibody polypeptides |
EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
US7598352B2 (en) | 2000-11-17 | 2009-10-06 | University Of Rochester | Method of identifying polypeptide monobodies which bind to target proteins and use thereof |
AU2002307146B2 (en) | 2001-04-04 | 2007-02-01 | University Of Rochester | AlphaNuBeta3 integrin-binding polypeptide monobodies and their use |
US20030082630A1 (en) | 2001-04-26 | 2003-05-01 | Maxygen, Inc. | Combinatorial libraries of monomer domains |
WO2003022858A2 (de) | 2001-09-11 | 2003-03-20 | Nascacell Gmbh | Verfahren zum screenen von inhibitoren für die protein-protein-wechselwirkung sowie ribozyme hierzu |
US20080193445A1 (en) | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
AU2003243436A1 (en) | 2002-06-06 | 2003-12-22 | Shohei Koide | Reconstituted polypeptides |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US20080220049A1 (en) | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
RU2402567C2 (ru) | 2003-12-05 | 2010-10-27 | Бристоль-Майерз Сквибб Компани | Ингибиторы рецепторов фактора роста эндотелия сосудов типа 2 |
EP1786918A4 (en) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | NEW BISPECIFIC ANTIBODY TETRAVALENT |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
BRPI0616883A2 (pt) | 2005-10-07 | 2011-07-05 | Univ California | ácidos nucléicos que codificam enzima modificada de citocromo p450 e métodos de uso dos mesmos |
CN103432568A (zh) | 2005-11-23 | 2013-12-11 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
AU2007218318A1 (en) | 2006-02-24 | 2007-08-30 | Chiesi Farmaceutici S.P.A. | Anti-amyloid immunogenic compositions, methods and uses |
EP2013229A2 (en) | 2006-04-21 | 2009-01-14 | Transgene S.A. | Hpv-18-based papillomavirus vaccine |
WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
JP2010507099A (ja) | 2006-10-16 | 2010-03-04 | ザ アリゾナ ボード オブ リージェンツ ア ボディ コーポレイト オブ ザ ステイト オブ アリゾナ アクティング フォー アンド オン ビハーフ オブ アリゾナ ステイト ユニバーシティー | 合成抗体 |
MX2009005466A (es) | 2006-11-22 | 2009-08-17 | Adnexus A Bristol Myers Sqibb | Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i. |
US20100144599A1 (en) | 2007-02-02 | 2010-06-10 | Bristol-Myers Squibb Company | Vegf pathway blockade |
JP2010520204A (ja) | 2007-03-02 | 2010-06-10 | アムジェン インコーポレイテッド | 腫瘍疾患を治療するための方法および組成物 |
AU2008287426B2 (en) | 2007-08-10 | 2014-06-26 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
US20100285000A1 (en) | 2007-08-20 | 2010-11-11 | Bristol-Myers Squibb Company | Use of vegfr-2 inhibitors for treating metastatic cancer |
BRPI0818810A2 (pt) | 2007-10-31 | 2014-10-29 | Medimmune Llc | Esqueletos d polipeptídeo recombinante e multimérico, molécula de ácido n ucleico isolado, vetor de expressão, célula hospedeira, biblioteca de exibição de polipeptídeo, coleção de moléculas de ácido nucleico isolado, métodos para obter um esqueleto de polipeptídeo e pelo menos dois esqueletos, para detectar um composto em uma amostra, para capturar um composto em uma amostra, para prevenir, tratar, controlar ou melhorar uma doença, para diagnose ou formação de imagem de uma doença para purificar e produzir um esqueleto, para ensaiar ou detectar a ligação de um esqueleto a um alvo, para usar o esqueleto e para prevenir, tratar, melhora ou controlar câncer, composição estéril, isenta de pirógeno, composição farmacêutica, e, processo escalável. |
WO2009073115A1 (en) | 2007-11-28 | 2009-06-11 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with mtor inhibitors |
WO2009086116A2 (en) | 2007-12-19 | 2009-07-09 | Centocor, Inc. | Alternative scaffold protein fusions phage display via fusion to plx of m13 phage |
CA2710835A1 (en) * | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
EP2247615B1 (en) | 2008-02-14 | 2014-07-30 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind egfr |
AU2009242038B2 (en) * | 2008-05-02 | 2013-05-30 | Novartis Ag | Improved fibronectin-based binding molecules and uses thereof |
EP2799448A1 (en) | 2008-05-22 | 2014-11-05 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
HUE030471T2 (en) | 2008-10-31 | 2017-05-29 | Janssen Biotech Inc | III. fibronectin-based framework products, methods and applications |
TWI496582B (zh) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | 雙重專一性之egfr/igfir結合分子 |
EA201100943A1 (ru) | 2008-12-16 | 2012-05-30 | Новартис Аг | Системы дрожжевого дисплея |
US20100210511A1 (en) | 2009-02-11 | 2010-08-19 | Bristol-Myers Squibb Company | Combination VEGFR2 Therapy with Temozolomide |
CA2752211C (en) | 2009-02-12 | 2020-03-24 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
US8067201B2 (en) | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
US20120270797A1 (en) | 2009-08-13 | 2012-10-25 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
EP2494046B1 (en) | 2009-10-30 | 2018-09-12 | Novartis AG | Universal fibronectin type iii bottom-side binding domain libraries |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
WO2011100700A2 (en) | 2010-02-12 | 2011-08-18 | University Of Rochester | Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
KR20130010461A (ko) * | 2010-02-18 | 2013-01-28 | 브리스톨-마이어스 스큅 컴퍼니 | Il―23에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질 |
US20130079280A1 (en) | 2010-04-13 | 2013-03-28 | Medlmmune, Llc | Fibronectin type iii domain-based multimeric scaffolds |
AR081454A1 (es) * | 2010-04-13 | 2012-09-05 | Bristol Myers Squibb Co | Proteinas de dominio de armazon basadas en fibronectina que se unen a pcsk9 (proproteina convertasa subtilisina kexina 9) |
EP2571531B1 (en) | 2010-04-30 | 2016-06-22 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
CN107903321A (zh) | 2010-07-30 | 2018-04-13 | 诺华有限公司 | 纤连蛋白摇篮分子和其库 |
EP2655411A1 (en) | 2010-12-22 | 2013-10-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind il-23 |
EP3415528B1 (en) | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
EP2709669A1 (en) | 2011-05-17 | 2014-03-26 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
EP2710382B1 (en) | 2011-05-17 | 2017-10-18 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
KR102035713B1 (ko) | 2011-09-27 | 2019-10-24 | 얀센 바이오테크 인코포레이티드 | 대체 결합 표면을 가진 피브로넥틴 유형 iii 반복체 기반의 단백질 스캐폴드 |
CN104053670A (zh) | 2011-10-31 | 2014-09-17 | 百时美施贵宝公司 | 具有降低的免疫原性的纤连蛋白结合域 |
MY189682A (en) | 2012-09-13 | 2022-02-25 | Bristol Myers Squibb Co | Fibronectin based scaffold domain proteins that bind to myostatin |
US20160152686A1 (en) * | 2013-03-13 | 2016-06-02 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto |
EA034886B1 (ru) | 2014-03-20 | 2020-04-02 | Бристол-Майерс Сквибб Компани | Связывающие сывороточный альбумин домены фибронектина iii типа |
AU2015231210B2 (en) | 2014-03-20 | 2019-09-12 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
ES2967078T3 (es) * | 2015-09-23 | 2024-04-25 | Bristol Myers Squibb Co | Dominios de fibronectina de tipo III de unión a seroalbúmina con velocidad de disociación rápida |
-
2015
- 2015-03-19 EA EA201691669A patent/EA034886B1/ru not_active IP Right Cessation
- 2015-03-19 JP JP2016558031A patent/JP6591437B2/ja active Active
- 2015-03-19 WO PCT/US2015/021535 patent/WO2015143199A1/en active Application Filing
- 2015-03-19 IL IL275497A patent/IL275497B/en unknown
- 2015-03-19 EP EP19170042.6A patent/EP3572424B1/en active Active
- 2015-03-19 SG SG11201607820QA patent/SG11201607820QA/en unknown
- 2015-03-19 AU AU2015231170A patent/AU2015231170B2/en active Active
- 2015-03-19 US US15/127,166 patent/US10442851B2/en active Active
- 2015-03-19 ES ES15714135T patent/ES2736127T3/es active Active
- 2015-03-19 CN CN201580014557.3A patent/CN106170494B/zh active Active
- 2015-03-19 EP EP15714135.9A patent/EP3129401B1/en active Active
- 2015-03-19 CA CA2943241A patent/CA2943241C/en active Active
- 2015-03-19 KR KR1020227041649A patent/KR20220162886A/ko not_active Application Discontinuation
- 2015-03-19 ES ES19170042T patent/ES2913840T3/es active Active
- 2015-03-19 MX MX2016011580A patent/MX2016011580A/es unknown
- 2015-03-19 CN CN202110321688.3A patent/CN113150117A/zh active Pending
- 2015-03-19 EA EA202090216A patent/EA202090216A3/ru unknown
- 2015-03-19 KR KR1020167028794A patent/KR102472862B1/ko active IP Right Grant
-
2016
- 2016-09-14 IL IL247825A patent/IL247825B/en active IP Right Grant
-
2019
- 2019-08-23 US US16/549,462 patent/US11203630B2/en active Active
- 2019-09-18 JP JP2019168989A patent/JP7132898B2/ja active Active
-
2021
- 2021-11-16 US US17/527,238 patent/US20220204589A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016011580A (es) | Dominios de fibronectina tipo iii que se unen a albumina de suero. | |
TN2012000518A1 (en) | Serum albumin binding molecules | |
PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
MX2017006866A (es) | Pares de unión para producción de péptidos. | |
WO2017053619A8 (en) | Glypican-3binding fibronectin based scafflold molecules | |
IL251194A0 (en) | Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria | |
DK3265478T3 (da) | Fusionsproteiner, der omfatter et bindingsprotein og et interleukin-15-polypeptid med reduceret affinitet til il15ra, og terapeutiske anvendelser deraf | |
SG10201909716RA (en) | Modified j-chain | |
MX363533B (es) | Proteínas de fusión que comprenden partes de unión a pdgf y vegf y métodos de uso de las mismas. | |
IL282960B (en) | Type iii fibronectin binding sites for serum albumin | |
MX2013015324A (es) | Polipeptidos de fusion con domino de proteína ácida del suero, y métodos de uso de los mismos. | |
EP3275895A4 (en) | Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof | |
MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
MX2021012047A (es) | Polipeptidos de fusion de serpina y metodos para utilizar los mismos. | |
IL271268A (en) | A fusion protein that extends half-life | |
MY176200A (en) | Binding polypeptides having a mutated scaffold | |
MX2015000754A (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
NZ731491A (en) | Cd83 binding proteins and uses thereof | |
MX2017005310A (es) | Metodos basados en proximidad para seleccion de parejas para ligadura. | |
MX2021009154A (es) | Selectividad eficaz de proteinas recombinantes. |